0.60Open0.42Pre Close11 Volume97 Open Interest7.50Strike Price609.00Turnover157.01%IV28.72%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type-0.1949Delta0.0671Gamma17.85Leverage Ratio-0.0217Theta-0.0016Rho-3.48Eff Leverage0.0072Vega
Cybin Stock Discussion
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
$NVIDIA (NVDA.US)$ $Tesla (TSLA.US)$ $SoFi Technologies (SOFI.US)$
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
EXCLUSIVE: Cybin Tells Benzinga Co. Announces Grant Of First U.S Composition of Matter Patent N Support Of Its CYB005 Phenethylamines Program
No comment yet